

# Jan Bolinder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7197921/publications.pdf>

Version: 2024-02-01

25  
papers

2,638  
citations

687363

13  
h-index

610901

24  
g-index

25  
all docs

25  
docs citations

25  
times ranked

2705  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. <i>Lancet, The</i> , 2016, 388, 2254-2263.	13.7	723
2	Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1020-1031.	3.6	689
3	Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 379.	7.4	520
4	Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. <i>Diabetologia</i> , 1998, 41, 1343-1354.	6.3	197
5	Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. <i>Diabetologia</i> , 2018, 61, 539-550.	6.3	124
6	A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3). <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 274-284.	4.4	88
7	Site Differences in Insulin Receptor Binding and Insulin Action in Subcutaneous Fat of Obese Females*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1983, 57, 455-461.	3.6	73
8	Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds. <i>Diabetes/Metabolism Research and Reviews</i> , 2000, 16, 442-447.	4.0	53
9	Phosphodiesterase Activity in Human Subcutaneous Adipose Tissue in Insulin- and Noninsulin-Dependent Diabetes Mellitus*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1982, 55, 983-988.	3.6	35
10	Effect of flash glucose monitoring in adults with type 1 diabetes: a nationwide, longitudinal observational study of 14,372 flash users compared with 7691 glucose sensor naive controls. <i>Diabetologia</i> , 2021, 64, 1595-1603.	6.3	34
11	Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI. <i>Diabetes Care</i> , 2021, 44, 141-149.	8.6	19
12	Design and Methods of a Randomized Trial of Continuous Glucose Monitoring in Persons With Type 1 Diabetes With Impaired Glycemic Control Treated With Multiple Daily Insulin Injections (GOLD Study). <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 754-761.	2.2	18
13	AAPS-FDA workshop white paper: Microdialysis principles, application, and regulatory perspectives report from the Joint AAPS-FDA Workshop, November 4-5, 2005, Nashville, TN. <i>AAPS Journal</i> , 2007, 9, E48-E59.	4.4	16
14	New Insulins, Biosimilars, and Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, S-57-S-78.	4.4	9
15	The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5). <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 619-630.	4.4	9
16	Cutaneous adverse events related to FreeStyle Libre device – Authors' reply. <i>Lancet, The</i> , 2017, 389, 1396-1397.	13.7	8
17	New Insulins, Biosimilars, and Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, S-46-S-68.	4.4	5
18	New Insulins, Biosimilars, and Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, S-43-S-55.	4.4	4

#	ARTICLE	IF	CITATIONS
19	Antilipolytic Effect of Insulin in Non-Insulin-Dependent Diabetes Mellitus after Conventional Treatment with Diet and Sulfonylurea. <i>Acta Medica Scandinavica</i> , 1988, 224, 451-459.	0.0	3
20	New Insulins, Biosimilars, and Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, S-55-S-70.	4.4	3
21	Flash glucose monitoring: objective, not self-referential, outcomes are needed. Reply to Warren RE [letter]. <i>Diabetologia</i> , 2018, 61, 1879-1880.	6.3	3
22	New Insulins and Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, S-39-S-46.	4.4	2
23	Evaluation of Effects of Continuous Glucose Monitoring on Physical Activity Habits and Blood Lipid Levels in Persons With Type 1 Diabetes Managed With Multiple Daily Insulin Injections: An Analysis Based on the GOLD Randomized Trial (GOLD 8). <i>Journal of Diabetes Science and Technology</i> , 2024, 18, 89-98.	2.2	2
24	New Insulins, Biosimilars, and Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, S-32-S-46.	4.4	1
25	New Insulins, Biosimilars, and Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, S-35-S-57.	4.4	0